Clinical Trials on Refractory Hairy Cell Leukemia

Total 5162 results

National Cancer Institute (NCI)

Completed

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia

United States
Michael Burke
Amgen

Recruiting

Blinatumomab Bridging Therapy

Refractory B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company

Completed

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Hodgkins Disease | Relapsed/Refractory Chronic Lymphocytic Leukemia | Relapsed Refractory Multiple Myeloma | Relapsed/Refractory Non Hodgkin's Lymphoma

United States
University Hospital, Clermont-Ferrand

Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (RAVEN)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | CLL | Relapsed Chronic Lymphocytic Leukemia | Progressive Chronic Lymphocytic Leukemia

France
M.D. Anderson Cancer Center
Genentech, Inc.

Withdrawn

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Refractory B-cell Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
First Affiliated Hospital of Harbin Medical University

Unknown

Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation

CD19-chimeric Antigen Receptor T Cells | Relapsed and/or Refractory Acute Lymphoblastic Leukemia | the Haploidentical Hematopoietic Stem Cell Transplantation

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States, Italy
Versailles Hospital

Recruiting

Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (ALLTARGETOBS)

T-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory Acute Lymphoblastic Leukemia

France
AstraZeneca

Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

India
Stanford University
Amgen; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (POE14-01)

Refractory Leukemia | Refractory Solid Tumors | Relapsed Solid Tumors | Relapsed Leukemia

United States, Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc; William Lawrence and Blanche Hughes Foundation

Active, not recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Relapsed Acute Lymphoblastic Leukemia (ALL) | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed Acute Myelogenous Leukemia (AML) | Refractory Acute Myelogenous Leukemia (AML) | Relapsed Mixed Lineage Leukemia | Refractory Mixed Lineage Leukemia | Relapsed Biphenotypic Leukemia | Refractory... and other conditions

United States
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditions

United States
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | T-Cell Prolymphocytic Leukemia | B-Cell Prolymphocytic Leukemia

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...

Unknown

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia

China
National Cancer Institute (NCI)

Terminated

Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
medac GmbH

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Hairy Cell | Lymphoma, Mantle-cell

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Masonic Cancer Center, University of Minnesota

Completed

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | MDS | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Refractory Anemia

United States
Autolus Limited

Active, not recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

United States, United Kingdom, Spain
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Pfizer

Completed

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

India
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
French Innovative Leukemia Organisation
Janssen, LP

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

Relapsed or Refractory Chronic Lymphocytic Leukemia

France
Celgene

Completed

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Relapsed or Refractory Chronic Lymphocytic Leukemia

United States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Recurrent T-Cell... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage

United States
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
University of Pennsylvania

Terminated

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States, Germany, Italy
Hospital Universitario La Paz

Completed

"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia (LYDIA)

Relapsed/Refractory Paediatric Acute Leukaemia

Spain
Shenzhen University General Hospital

Unknown

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia (CAR-T)

Refractory B Acute Lymphoblastic Leukemia | Relapse | B ALL | Dual-target CAR-T Cells

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States

Clinical Trials on Refractory Hairy Cell Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations